Meaghan P Granger

5PUBLICATIONS
44CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersRadiation therapyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 07, 2022
Progression-Free Survival and Patterns of Response in Patients With Relapsed High-Risk Neuroblastoma Treated With Irinotecan/Temozolomide/Dinutuximab/Granulocyte-Macrophage Colony-Stimulating Factor.

Benjamin J Lerman, Yimei Li, Cecilia Carlowicz

|Jul 12, 2022
Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321).

Ira J Dunkel, Jin Piao, Guillermo L Chantada

|Dec 09, 2021
Predicting Response to Chemotherapy in Patients With Newly Diagnosed High-Risk Neuroblastoma: A Report From the International Neuroblastoma Risk Group.

Anoop Mayampurath, Siddhi Ramesh, Diana Michael

|Jul 16, 2021
Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium.

Steven G DuBois, M Meaghan Granger, Susan Groshen

|Dec 21, 2016
Enrichment of Targetable Mutations in the Relapsed Neuroblastoma Genome.

Olivia M Padovan-Merhar, Pichai Raman, Irina Ostrovnaya

Pageof 1

Frequent Collaborators

3 joint publications

Brian Weiss

2 joint publications

Navin Pinto

2 joint publications

Suzanne Shusterman

2 joint publications

Susan L Cohn